Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 40.22 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 12.72 | Oscillator | Buy |
| Williams %R (14) | -86.26 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.13 (Hist -0.06) | Oscillator | Strong Sell |
| Average Directional Index (14) | 24.64 (+DI 18.1 / -DI 26.9) | Trend | Sell |
Current price $2.31
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 5, 26 | HC Wainwright & Co. |
| EMA 20 | 2.52 | MA | Strong Sell |
| SMA 20 | 2.69 | MA | Strong Sell |
| EMA 50 | 2.66 | MA | Strong Sell |
| SMA 50 | 2.62 | MA | Strong Sell |
| SMA 200 | 3.65 | MA | Strong Sell |
| maintain |
| Buy |
| Buy |
| Aug 12, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 10, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Jul 15, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 13, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 9, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 23, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 22, 26 | D. Boral Capital | maintain | Buy | Buy |
| Apr 8, 26 | D. Boral Capital | maintain | Buy | Buy |
Stock news · updated daily
CervoMed Inc. (NASDAQ:CRVO) reported early results from its Phase 2a clinical study evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA).
CervoMed (NASDAQ: CRVO - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Monday, MarketBeat reports. A number of other brokerages have also weighed in on CRVO. Wall Street Zen upgraded CervoMed from a "strong sell" rating to a "sell" rating in a research
CervoMed Inc. (NASDAQ: CRVO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has issued a
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15 th International Conference on Frontotemporal Dementia (ISFTD) in October 2026; full 12-week and initial, 24-week biomarker data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2026 Completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million, extending cash runway through the third quarter of 2027 BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was marked by meaningful progress across both our business and pipeline.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -0.87 | -0.64 | Beat 26.4% | — |
| May 18, 2026 | -0.90 | -0.86 | Beat 4.4% | — |
| Mar 13, 2026 | -0.79 | -0.88 | Miss -11.4% | $6.51K |
| Nov 7, 2025 | -0.68 | -0.84 | Miss -23.5% | $322.6K |
| Aug 8, 2025 | -0.61 | -0.70 | Miss -13.9% | $1.76M |
| May 12, 2025 | -0.60 | -0.56 | Beat 6.7% | $1.92M |
TTM vs. 5-year historical average (annual ratios)
| Metric | CRVO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.7x | -3.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.1x | EPS est. -2.15 | Elevated |
| Price / Book | 1.0x | 1.5x | Discount |
| Price / Sales | 108.3x | — | n/a |
| EV / EBITDA | -0.4x | -2.1x | Discount |
| Return on equity | -156.0% | — | Weak |
| Gross margin | 100.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | -0.28 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -1.91 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 22, 26 | Blackburn Kelly | officer: EVP, Clinical Development | A-Award | 19,100 @ $2.24 | $42.78K |
| Oct 22, 26 |
| De Rosch Mark |
| officer: EVP, RA and GA and PgM |
| A-Award |
| 19,100 @ $2.24 |
| $42.78K |
| Oct 22, 26 | Winton Matthew | officer: Chief Commercial and Business | A-Award | 19,100 @ $2.24 | $42.78K |
| Jun 11, 26 | Boger Joshua S | director, 10 percent owner: | P-Purchase | 955,414 @ $3.14 | $3.00M |
| Jun 11, 26 | Boger Joshua S | director, 10 percent owner: | P-Purchase | 955,414 @ $3.32 | $3.17M |
| Jun 11, 26 | Boger Joshua S | director, 10 percent owner: | P-Purchase | 955,414 @ $3.14 | $3.00M |
| Jun 8, 26 | Zavrl Frank | director | A-Award | 8,150 @ $2.91 | $23.72K |
| Jun 8, 26 | Sabbagh Marwan | director | A-Award | 8,150 @ $2.91 | $23.72K |
| 8-K | Oct 13, 2026 | 2026-10-13 08:36:31 | View |
| 8-K | Oct 9, 2026 | 2026-10-09 16:06:30 | View |
| 8-K | Sep 28, 2026 | 2026-09-28 17:07:31 | View |
| 8-K | Sep 10, 2026 | 2026-09-10 16:07:55 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:41:21 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 14:42:20 | View |
Proxy statement (DEF 14A) disclosures